Pacific released a research report on April 23 stating that Xianle Health (300791.SZ) was given a purchase rating, and the target price was 45.05 yuan. The main reasons for the rating include: 1) high revenue growth for the full year of 2023; 2) the endogenous net interest rate reached a record high in 2023, and the level of endogenous profit increased beyond expectations in 2024Q1; 3) it is expected that rapid growth will continue in 2024, and the equity incentive target will be successfully achieved. (Mainichi Keizai Shimbun)
太平洋4月23日发布研报称，给予仙乐健康（300791.SZ）买入评级，目标价格为45.05元。评级理由主要包括：1）2023年全年高增收官，2024Q1美洲恢复高弹性增长；2）2023年内生净利率达历史新高，2024Q1内生盈利水平提升超预期；3）2024年预计延续较快增长，股权激励目标有望顺利达成。（每日经济新闻）
Pacific released a research report on April 23 stating that Xianle Health (300791.SZ) was given a purchase rating, and the target price was 45.05 yuan. The main reasons for the rating include: 1) high revenue growth for the full year of 2023; 2) the endog
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.